Page 189 - Genentech News Today

NEW ORLEANS — Izokibep, a novel interleukin-17 inhibitor, has shown dramatic responses in hidradenitis suppurativa treatment in an early phase 2 study, according to a speaker at the American Academy of Dermatology Annual Meeting.“[Hidradenitis suppurativa (HS)] is a horrible, horrible disease with a high disease burden. It’s extremely disruptive to anyone’s personal

Dublin, March 23, 2023 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Global Market Report 2023" report has been added to ...

Despite a strong start last year, venture capital funding for life sciences totaled $35.8 billion in 2022, down 28% from 2021, according to Cushman & Wakefield (C&W). Initial public...

With around 4 million podcasts in the audioscape, it can be hard to parse through what is good and what is, well—trash.

I don’t think I have to explain in these pages how difficult it is to find a drug that can be effective as a chemotherapeutic agent.

The main representatives of Hispanic leadership organizations will be present.

According to new research, therapies may cause lymph nodes to produce tumour-fighting T cells.

Get latest articles and stories on Health at LatestLY. According to new research, therapies may cause lymph nodes to produce tumour-fighting T cells. Health News | Study Finds How Lymph Nodes Boost Tumor Cells After Success of Immunotherapy.

/PRNewswire/ -- Emtrain, an edtech company, today announced the launch of Emtrain Analytics, a new way to measure workplace inclusion and respect within an...

To combine thoroughness, speediness, and economy, single-cell proteomics embraces novel technologies for sample preparation, labeling, and multiplexing.